Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?

Cytokinetics faces a Dec. 26 PDUFA for aficamten, a cardiac myosin inhibitor positioned to compete with BMS’s Camzyos; an approval would be the company’s first U.S. launch after 27 years. The asset received a China approval that triggered a $7.5M Sanofi milestone and has shown positive Phase III MAPLE‑HCM data and faster two‑week titration versus Camzyos, which generated >$600M in 2024. Analysts model varied peak sales (Truist: $3.4B oHCM + $460M non‑obstructive; company/CEO: $4B peak in oHCM and up to $10B if expanded), and Cytokinetics plans to commercialize in the U.S./EU while potentially partnering internationally.

Analysis

MARKET STRUCTURE: Approval of aficamten (PDUFA Dec 26) would immediately make CYTK a commercial-stage cardiology biotech and create a two-player oHCM duopoly with BMS’ Camzyos. Management claims aficamten’s faster 2-week titration is a distributable commercial edge that could drive share gains—modeling scenarios: 30–60% share of a ~$1B oHCM market in 2–3 years, scaling toward management’s $4B peak if non‑obstructive HCM is captured. Pricing power should remain strong initially (high ASPs typical in orphan cardio), but incremental competition caps long-term pricing expansion absent clear superiority.

RISK ASSESSMENT: The immediate (days) tail risk is a PDUFA denial or restrictive REMS labeling (estimate 20–30% downside probability); short-term (weeks–months) risks include reimbursement/PA friction and launch execution; long-term (1–5 years) risks include failed ACAIA-HCM readout, IP litigation from prior developer, or aggressive competitor pricing. Hidden dependencies: CYTK must build US/EU commercial capability or sign partners quickly—failure increases dilution or delays peak sales. Key catalysts: Dec 26 PDUFA, any FDA label/REMS within 48–72 hours post-action, ACAIA-HCM Phase III readout timing.

TRADE IMPLICATIONS: Event trade: asymmetric exposure to CYTK; prefer limited-loss option structures over naked equity into PDUFA. For directional investors, a 2–3% long equity position in CYTK entered 7–10 trading days pre‑PDUFA with a 25–30% stop is reasonable; for tactical leverage, buy a Mar-2026 call debit spread sized to risk 0.5–1% of portfolio. Hedging: pair long CYTK with short beta‑matched IBB (equal dollar) for 90 days to isolate idiosyncratic approval risk, or buy 90-day 25‑delta puts/put-spreads if holding larger positions.

CONTRARIAN ANGLES: Consensus may underprice aficamten’s faster titration operational benefit—if real-world adoption is rapid, CYTK could outgrow peak estimates (>$4B) faster than models assume, especially if ACAIA shows benefit in non‑obstructive HCM. Conversely, market may be underestimating commercialization strain and payer pushback; a conservative scenario where uptake is 25–40% of modeled peak should be priced in. Historical parallel: MyoKardia/BMS shows incumbents can still lose share to follow‑ons with better dosing profiles; watch for REMS/pricing actions as the pivotal swing factors.

Key Decisions for Investors

• Establish a tactical 2–3% long position in CYTK (equity) entering 7–10 trading days before the Dec 26 PDUFA; set a hard stop-loss at 25–30% to limit binary-event downside and scale to full size only after label clarity within 72 hours post-PDUFA.
• For leveraged upside with defined risk, buy a CYTK Mar-2026 call debit spread (buy ~25‑delta call, sell a higher strike ~10–15% above) sized to risk 0.5–1% of portfolio; this captures approval upside while capping premium loss if FDA denies or IV collapses.
• If holding sizable CYTK exposure, hedge idiosyncratic risk by shorting equivalent dollar beta to IBB for 90 days (dollar-neutral) or purchase 90-day 25‑delta put or put-spread to cap downside to ~30% at known cost.
• Monitor within 48–72 hours after Dec 26 for full FDA label language and any REMS/prior authorization signals; if label restricts outpatient titration or mandates clinic-only dosing, reduce CYTK exposure by 50% immediately. Also, if ACAIA-HCM Phase III positive (expected within 12–24 months), add to CYTK up to another 2–3% given incremental TAM expansion potential.